Drug Approval | December 28, 2021
Dr Reddy’s receives Emergency Use Authorisation for molnupiravir
The company will market it under the brand name Molflu
The company will market it under the brand name Molflu
The company has developed the API in house at its R&D center in Hyderabad
This product will be manufactured at Lupin's Goa facility in India
The Home Healthcare market is expected to be US $ 14.2 by 2025
The authorization provides an additional treatment option against the Covid-19 virus in the form of a pill that can be taken orally
Systemic Lupus Erythematosus, or Lupus, is an autoimmune chronic inflammatory disease. The prevalence of SLE in the U.S. has been reported to be between 20 to 150 cases per 100,000. In India, the reported prevalence of SLE is 3.2 per 100,000
Alzheimer's disease is a serious, progressive and devastating disease with few treatment options
Pfizer raises production projections from 80 million to 120 million courses of treatment in 2022, as a result of continued investments to support the manufacturing and distribution of Paxlovid
Philips’s CavaClear is intended to safely ablate tissue to remove embedded IVC filters
The investment in Yapan Bio allows Piramal Pharma Solutions to broaden its service offerings in the fast-growing biologics CDMO space
Subscribe To Our Newsletter & Stay Updated
